Vertex Under Pressure To Spend On M&A
Company Has $6.7bn In Cash
The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development
You may also be interested in...
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
The results could help BI and Zealand Pharma challenge in the MASH field, though analysts are wary of claims around fibrosis improvement.